GT201300168A - Respuesta inmune potenciada en la especie bovina - Google Patents

Respuesta inmune potenciada en la especie bovina

Info

Publication number
GT201300168A
GT201300168A GT201300168A GT201300168A GT201300168A GT 201300168 A GT201300168 A GT 201300168A GT 201300168 A GT201300168 A GT 201300168A GT 201300168 A GT201300168 A GT 201300168A GT 201300168 A GT201300168 A GT 201300168A
Authority
GT
Guatemala
Prior art keywords
bovine species
immune response
potentiated
response potentiated
infectious diseases
Prior art date
Application number
GT201300168A
Other languages
English (en)
Inventor
Abraham Albert
Keil Daniel
Nickell Jason
Weiss Christian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201300168A publication Critical patent/GT201300168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN MÉTODO DE ACTIVACIÓN INMUNE QUE ES EFICAZ PARA PROVOCAR UNA RESPUESTA INMUNE NO ESPECÍFICA DE ANTÍGENO EN UN MIEMBRO DE LA ESPECIE BOVINA. EL MÉTODO ES PARTICULARMENTE EFICAZ PARA PROTEGER A UN MIEMBRO DE LA ESPECIE BOVINA DE LAS ENFERMEDADES INFECCIOSAS Y EL TRATAMIENTO DE ANIMALES INFLIGIDAS CON ENFERMEDADES INFECCIOSAS.
GT201300168A 2010-12-22 2013-06-21 Respuesta inmune potenciada en la especie bovina GT201300168A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061426255P 2010-12-22 2010-12-22

Publications (1)

Publication Number Publication Date
GT201300168A true GT201300168A (es) 2015-02-23

Family

ID=45444595

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300168A GT201300168A (es) 2010-12-22 2013-06-21 Respuesta inmune potenciada en la especie bovina

Country Status (34)

Country Link
US (3) US20130295167A1 (es)
EP (1) EP2654785B1 (es)
JP (2) JP6058550B2 (es)
KR (1) KR101940826B1 (es)
CN (2) CN103501810A (es)
AR (1) AR084510A1 (es)
AU (1) AU2011347464B2 (es)
BR (1) BR112013016231B1 (es)
CA (1) CA2822359C (es)
CL (1) CL2013001833A1 (es)
CO (1) CO6761354A2 (es)
CR (1) CR20130312A (es)
DK (1) DK2654785T3 (es)
DO (1) DOP2013000149A (es)
EC (1) ECSP13012709A (es)
ES (1) ES2722204T3 (es)
GT (1) GT201300168A (es)
HK (1) HK1259341A1 (es)
HR (1) HRP20190779T1 (es)
HU (1) HUE043473T4 (es)
IL (1) IL226733B (es)
LT (1) LT2654785T (es)
MX (1) MX345854B (es)
MY (1) MY167159A (es)
NZ (1) NZ612285A (es)
PL (1) PL2654785T3 (es)
PT (1) PT2654785T (es)
RU (1) RU2606855C2 (es)
SI (1) SI2654785T1 (es)
TR (1) TR201906323T4 (es)
TW (1) TWI587877B (es)
UA (1) UA118537C2 (es)
UY (1) UY33821A (es)
WO (1) WO2012084951A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ612285A (en) * 2010-12-22 2015-09-25 Bayer Ip Gmbh Enhanced immune response in bovine species
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
AU2015222102B2 (en) 2014-02-28 2021-08-19 Bayer Animal Health Gmbh Immunostimulatory plasmids
CN104825393B (zh) * 2015-01-16 2017-11-10 艾美科健（中国）生物医药有限公司 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法
US20190233825A1 (en) * 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
KR20180036765A (ko) * 2015-07-31 2018-04-09 바이엘 애니멀 헬스 게엠베하 돼지 종에서의 강화된 면역 응답성
WO2017021242A1 (en) * 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
SG11201900710YA (en) 2016-07-26 2019-02-27 Bayer Animal Health Gmbh Increased fertility in bovine species
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
MX2020006244A (es) * 2017-12-15 2020-09-03 Bayer Animal Health Gmbh Composiciones inmunoestimulantes.
CN108812546A (zh) * 2018-09-07 2018-11-16 四川省草原科学研究院 适于青藏高原地区牦牛运输减少应激的药物及使用方法
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用
WO2020194735A1 (ja) 2019-03-28 2020-10-01 日本電気株式会社 情報処理装置、サーバ割当装置、方法、及びコンピュータ可読媒体
CN114480663A (zh) * 2021-11-15 2022-05-13 贵州省畜牧兽医研究所 用于检测猪源差异脲原体的引物对、试剂盒及检测方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
ATE397942T1 (de) 1999-03-26 2008-07-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
RU2158587C1 (ru) * 1999-05-11 2000-11-10 Ставропольское научно-производственное объединение "Пульс" Антибактериальное средство для лечения заболеваний сельскохозяйственных животных и птиц, способ профилактики и лечения цыплят при заболеваниях бактериальной этиологии, способ лечения респираторной болезни телят бактериальной этиологии, способ профилактики туберкулеза у крупного рогатого скота
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
AR035869A1 (es) 2001-04-24 2004-07-21 Innogenetics Nv Proteinas de la envoltura de hcv glicosiladas en la estructura central, un metodo para producir la proteina de envoltura de hcv aislada, una composicion que la comprende, metodo para detectar la presencia de anticuerpos anti-hcv en una muestra, un kit de diagnostico para detectar la presencia de ant
EP1521592A2 (en) * 2001-07-02 2005-04-13 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
BRPI0408779A (pt) * 2003-03-26 2006-04-04 Wyeth Corp uso de composições, composição imunogênica e kit
AR044437A1 (es) * 2003-05-29 2005-09-14 Schering Plough Ltd Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino
JP2007509040A (ja) * 2003-10-11 2007-04-12 イネックス ファーマシューティカルズ コーポレイション 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
UY29915A1 (es) 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
JP2008094763A (ja) * 2006-10-12 2008-04-24 Takeshi Ogura 海洋ミネラル成分からなるインターフェロンγ産生増強剤
US20110111017A1 (en) * 2008-02-24 2011-05-12 Government Of The United States Of America,As Rep. By The Secretary,Dept. Of Health And Human Servic Use of immunogenic compositions for the treatment or prevention of pathogen infections
US8945590B2 (en) * 2008-03-25 2015-02-03 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-DNA complex (CLDC)
NZ591950A (en) * 2008-10-31 2012-12-21 Boehringer Ingelheim Vetmed Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
SI2429581T1 (sl) * 2009-05-14 2015-11-30 Bayer Intellectual Property Gmbh Povečan imunski odgovor v ptičjih vrstah
NZ612285A (en) * 2010-12-22 2015-09-25 Bayer Ip Gmbh Enhanced immune response in bovine species

Also Published As

Publication number Publication date
AR084510A1 (es) 2013-05-22
BR112013016231B1 (pt) 2021-03-23
HUE043473T2 (hu) 2019-08-28
MX345854B (es) 2017-02-17
CO6761354A2 (es) 2013-09-30
DK2654785T3 (da) 2019-06-24
AU2011347464A2 (en) 2013-08-22
MY167159A (en) 2018-08-13
JP6058550B2 (ja) 2017-01-11
US20190201434A1 (en) 2019-07-04
AU2011347464B2 (en) 2016-08-25
TR201906323T4 (tr) 2019-05-21
UY33821A (es) 2012-07-31
BR112013016231A2 (pt) 2016-09-27
US20130295167A1 (en) 2013-11-07
KR101940826B1 (ko) 2019-01-21
ECSP13012709A (es) 2013-08-30
RU2606855C2 (ru) 2017-01-10
CN103501810A (zh) 2014-01-08
PT2654785T (pt) 2019-06-25
TWI587877B (zh) 2017-06-21
CL2013001833A1 (es) 2014-06-20
SI2654785T1 (sl) 2019-06-28
HUE043473T4 (hu) 2019-12-30
MX2013007064A (es) 2013-08-21
UA118537C2 (uk) 2019-02-11
TW201306877A (zh) 2013-02-16
IL226733B (en) 2020-06-30
WO2012084951A1 (en) 2012-06-28
JP2014500292A (ja) 2014-01-09
JP2017036290A (ja) 2017-02-16
HRP20190779T1 (hr) 2019-06-28
CN108379576A (zh) 2018-08-10
ES2722204T3 (es) 2019-08-08
CA2822359A1 (en) 2012-06-28
AU2011347464A1 (en) 2013-07-11
NZ612285A (en) 2015-09-25
EP2654785A1 (en) 2013-10-30
HK1259341A1 (zh) 2019-11-29
CA2822359C (en) 2021-06-01
PL2654785T3 (pl) 2019-09-30
EP2654785B1 (en) 2019-03-20
LT2654785T (lt) 2019-07-10
DOP2013000149A (es) 2013-08-15
US20140010865A1 (en) 2014-01-09
RU2013133730A (ru) 2015-01-27
CR20130312A (es) 2013-10-17
KR20130132926A (ko) 2013-12-05
US10751361B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
GT201300168A (es) Respuesta inmune potenciada en la especie bovina
CR20110595A (es) Respuesta inmunitaria reforzada en especies aviares
CY1123515T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CY1123672T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
UY35716A (es) Proteínas de unión al antígeno gitr
UY34995A (es) Formulaciones de anticuerpo y proteína
UY33202A (es) Proteínas de unión a cd127
BR112013009068A2 (pt) supressão de uma resposta imune de hipersensibilidade com antígeno não relacionado derivado de material fonte de alérgeno
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
CL2018003284A1 (es) Métodos de tratamiento de enfermedades autoinmunes usando linfocitos t alogénicos.
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
CL2016000392A1 (es) Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
CO2017001626A2 (es) Anticuerpo anti-orai1
CO2018002207A2 (es) Composiciones contra alergia a los gatos
TWD169884S (zh) 動物互動裝置
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
NI201300058A (es) Respuesta inmune potenciada en la especie bovina
BR112015028986A2 (pt) métodos para produzir partículas compreendendo proteínas terapêuticas
CO2019000724A2 (es) Aumento de la fertilidad en especies bovinas
AR106769A1 (es) Composiciones que comprenden cepas bacterianas
UY35706A (es) Vacuna contra nematodos de ovinos